Evidence map›Paper›PMID 40726554›Full record

ArticleGE Portuguese journal of gastroenterology2025

Olmesartan-Induced Gastropathy: An Important Cause to Think about in Refractory Peptic Ulcer Disease.

Diogo Simas, André Ruge Gonçalves, Plácido Gomes, Pedro Russo, Cristina M Amado, Helena Vasconcelos

Abstract read
In one paragraph

Article in GE Portuguese journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Diogo SimasServiço de Gastrenterologia, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.
André Ruge GonçalvesServiço de Gastrenterologia, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.
Plácido GomesServiço de Gastrenterologia, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.
Pedro RussoServiço de Gastrenterologia, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.
Cristina M AmadoServiço de Anatomia Patológica, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.
Helena VasconcelosServiço de Gastrenterologia, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Angiotensin receptor blockers are a pharmacological class widely used as antihypertensive therapy. Recently, a relationship between these agents and gastrointestinal disease has been described, namely, enteropathy, gastropathy, and microscopic colitis. The mechanism is unknown, but it is thought that a cell-mediated immune reaction is involved and does not appear to be a class effect. Treatment consists of stopping the drug and rechallenge can confirm the diagnosis. Case Presentation: An 85-year-old man with a history of hypertension treated with olmesartan/hydrochlorothiazide for 12 years presented to the emergency department with months of epigastric pain, without vomiting, blood loss, diarrhea, or weight loss. A recent upper gastrointestinal endoscopy (UGE) showed congested mucosa, irregular erosions, and friability in the distal body, notch, and antrum. Histology revealed moderate chronic gastritis, severe inflammatory activity, abundant eosinophils, intestinal metaplasia with low-grade dysplasia, and marked atrophy, with no signs of malignancy or Conclusions: This case report illustrates olmesartan-induced gastropathy, an important diagnosis to consider in cases of non-Hp gastritis and refractory peptic ulcer disease.

Indexed as

Angiotensin receptor blockersDrug-induced gastropathyRefractory peptic ulcer disease

Identifiers

PMID40726554
PMCPMC12296203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.